Biomet U.S. Hip Sales Advance 14% In Q1; Spine Revenues “Essentially Flat”
This article was originally published in The Gray Sheet
Executive Summary
Biomet's accelerated U.S. hip sales growth of 14% for its most recent fiscal quarter is attributable in part to difficulties facing its competitors, as well as the strength of products like its Taperloc hip system, M2a-Magnum acetabular system and E-Poly acetabular liners, according to the company
You may also be interested in...
Physician-Initiated Alert Sparks Zimmer Investigation Of Durom Hip Failures
Zimmer is investigating failures of its Durom hip implants after a prominent joint reconstruction surgeon sent a letter reporting a series of problems with the device to the American Association of Hip and Knee Surgeons
Stryker Ramps Up Compliance Spending, But Predicts Unimpeded Growth
Stryker is raising its stake in compliance activities in response to government scrutiny of its regulatory and sales practices, but the firm does not foresee a major hit to its bottom line
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.